Marija Blagoja Simonovska

Dr. Marija Blagoja Simonovska

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMarija Blagoja Simonovska
Marija Blagoja Simonovska
JDJasmina Djundeva
Jasmina Djundeva
BKBojana Petreska Kapsarov
Bojana Petreska Kapsarov
JSJulijana Stefanoska
Julijana Stefanoska
MSMarina Vukashinovik Stoleska
Marina Vukashinovik Stoleska
AEAleksandar Eftimov
Aleksandar Eftimov
Background/Objectives: Programmed death-ligand 1 (PD-L1) expression is commonly used as a predictive biomarker in metastatic non-small cell lung cancer (NSCLC); however, its clinical utility in real-world settings remains uncertain. This study evaluated the association between PD-L1 expression and treatment outcomes in patients receiving immune checkpoint inhibitors (ICIs). Methods: In this retrospective, single-center study, 86 patients with metastatic NSCLC treated with ICIs (pembrolizumab or atezolizumab) between January 2020 and December 2025 were included. PD-L1 expression was assessed using 22C3 or SP263 assays and categorized as <50% and ≥50%. The primary endpoint was time to progression (TTP), while the secondary endpoint was objective response rate (ORR). Survival analyses were performed using Kaplan–Meier estimates, log-rank tests, and Cox proportional hazards models. Results: PD-L1 data were available for 78 of the 86 patients. The median age was 66 years (IQR 61–73); 76.7% of patients were male and 65.1% were former smokers. Adenocarcinoma was the predominant histological subtype (47.7%), followed by squamous cell carcinoma (41.9%). The ORR was similar between treatment groups (atezolizumab: 62.5%; pembrolizumab: 64.9%; p = 0.84). No statistically significant difference in TTP was observed between PD-L1 <50% and ≥50% groups. Kaplan–Meier analysis showed no statistically significant difference in TTP between PD-L1 groups (log-rank p = 0.094), although a numerical trend toward shorter TTP was observed in patients with PD-L1 ≥50%. In multivariate Cox regression analysis, PD-L1 ≥50% was not associated with TTP (hazard ratio [HR] 1.53, 95% confidence interval [CI] 0.77–3.05; p = 0.20). No other clinical variables, including smoking status and liver metastases, were significantly associated with outcomes. Conclusions: In this limited, retrospective single-center cohort with a heterogeneous treatment mix (chemo-immunotherapy and immunotherapy monotherapy), PD-L1 expression was not significantly associated with treatment response or time to progression. While these results should be interpreted cautiously given the modest sample size and the small number of progression events, they are consistent with broader real-world evidence indicating that PD-L1 expression alone may not reliably stratify clinical benefit in metastatic NSCLC. Larger prospective studies integrating PD-L1 with complementary biomarkers are needed to confirm these observations.

10 October 2025 in Genes
Verified
Journal Article
Open access
PDF file
AEAleksandar Eftimov
Aleksandar Eftimov
RJRubens Jovanović
Rubens Jovanović
SKSlavica Kostadinova Kunovska
Slavica Kostadinova Kunovska
MTMagdalena Bogdanovska Todorovska
Magdalena Bogdanovska Todorovska
BIBoro Ilievski
Boro Ilievski
GPGordana Kiro Petrushevska
Gordana Kiro Petrushevska
Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer—BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA. Methods: Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations. Results: Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected. Conclusions: Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective.